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• Ebola Virus
• Outbreak and Disease
• Cost of Epidemic
• Vaccine Candidate
• Development at Merck







• Discovered in 1976 near the Ebola River 
in the Democratic Republic of the Congo
• Causes hemorrhagic fever; severe 
headache, muscle pain, weakness, 
fatigue, diarrhea, vomiting, abdominal 
pain, bleeding/bruising
• Spread through direct contact with body 
fluids of infected humans/animals





“The 2014–2016 outbreak in West Africa 
was the largest and most complex 
Ebola outbreak since the virus was first 
discovered in 1976. 
There were more cases and deaths in 
this outbreak than all others combined”
28,616 Total Cases Reported 
in Guinea, Liberia, and Sierra 
Leone with 11,310 Deaths as 
of 27Mar2016 (latest update)
2014 – 2016 Outbreak
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>11X larger than all previous 
outbreaks combined
>11k deaths
$2.2B in GDP lost in Guinea, 
Liberia, Sierra Leone in 2015
>$3.6B spent to fight the 





Ebola cases occurred in 2017 and a new 
outbreak started in 2018.
World Health Organization:
“Vaccination will be the key to controlling this 
outbreak”  Dr. Tedros Adhanom Ghebreyesus, WHO 
Director General
The Vaccine Candidate: rVSVΔG-ZEBOV-GP (V920)
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https://www.popsci.com/best-of-whats-new-2015/healthcare
• A vaccine candidate was developed
• Clinical studies were a global 
effort – supported by many 
countries and health agencies
• Results from a ring vaccination 
trial suggests the V920 vaccine 
has high protective efficacy and 
effectiveness 
• The vaccine was in-licensed by 
Merck who took on the responsibility 
for research, development, and 
manufacturing efforts
V920 Development at Merck
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On Nov 24th 2014 Merck announced an exclusive worldwide agreement with NewLink Genetics to 
research, develop, manufacture, distribute, and license V920, an investigational vaccine candidate.
Merck began work on V920 in 2015 
• Process Development Scope and Goals:
• Process scale-up in support of Emergency Use and commercial dose production
• Increase lot size from clinical manufacturing scale
• Show comparability between clinical and commercial scale
• Process development and characterization to fully define a robust manufacturing process
• Generate lab-scale data to support process parameter ranges
• Define the Final Manufacturing Process (FMP) Description
• New approaches were needed to accelerate development and characterization work
1. Work in parallel
2. Use a risk-based approach to prioritize development studies
3. Create and use a scale-down model to increase experiment throughput
4. Consider single-use solutions
V920 Development at Merck
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Approach 1: Work in Parallel
• Team 1: Scale-up and emergency use production
• Team 2: Process Development and FMP definition














• A team of live viral vaccine 
SMEs evaluated the clinical 
manufacturing process with a 
risk assessment to help identify 
unit operations and process 
parameters in need of study
• Unit operations and parameters 



















V920 Development at Merck
Approach 3: Develop a Scale-Down Model for experimental work
• Reduced cycle time to generate data
• Reduced from 8+ weeks to 3 weeks 
• Reduced purification process volume from 80L to 
1L to enable design of experiments
• Infection – cell/virus interactions
• Purification – enzyme reaction interactions















• 450+ vials of cells used for lab-scale 
experiments
• 200+ experiment notebooks generated and 
reviewed
• First draft of FMP issued within 1 year of project 
start
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V920 Development at Merck
Multiplicity of Infection (MOI) Robustness
• MOI typically a very sensitive 
parameter for infection
• Within our target harvest window a 
1000x MOI range is capable of 
producing drug substance bulks with 
the same range of potencies









V920 Development at Merck
Purification Robustness
• Multifactor DOE performed looking at enzyme 
reaction parameters
• Only the time that the enzyme was added to 
reaction was found to be statistically significant 
to achieve the desired potency increase
• Failure point used to set PAR
• Tangential Flow Filtration capable of robustly 

















PAR, proven acceptable range
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V920 Development at Merck
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PFD, process flow diagram
URS, user requirement specifications
RFP, request for proposal
VOC, voice of customer
Approach 4: Develop a Single-Use Drug Substance Process
• Desire for modular single-use components with sterile connectors
Month 0-5
• Design and scale-up














• Evaluate designs – obtain VOC, to 
support component design 
simultaneously with operations staff 
onboarding and facility retrofit
• Hands-on training and team building
• Assembly layout for process and 
area fit
• Began to understand waste streams
VOC, voice of customer
V920 Development at Merck
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Approach 4: Develop a Single-Use Drug Substance Process
• Final process is 100% single-use
• >500 assemblies made from 42 modular 
designs
• Established a platform approach for 
future vaccines
• Allowed for rapid transfer to the 
manufacturing site (15 months)
Month 0-5
• Design and scale-up


















• Signed-off on 
last component
• All orders 
placed
Month 15
• Components start 
to be delivered
PFD, process flow diagram
URS, user requirement specifications
RFP, request for proposal
VOC, voice of customer
• Desire for modular single-use components with sterile connectors
Conclusions
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Several approaches were used to expedite process development and characterization 
of the V920 vaccine candidate and develop a robust process:
1. Work in parallel
2. Use a risk-based approach to prioritize development studies
3. Create and use a scale-down model to increase experiment throughput
4. Robust Process Results from experiments
1. A 1000x MOI range produces acceptable potencies
2. Enzyme addition is critical for achieving expected potency increase during 
purification
3. TFF robustly clears process residuals
5. Consider single-use solutions
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